3.71
+0.07(+1.92%)
Currency In USD
| Previous Close | 3.64 |
| Open | 3.68 |
| Day High | 3.83 |
| Day Low | 3.52 |
| 52-Week High | 12.46 |
| 52-Week Low | 1.15 |
| Volume | 122,944 |
| Average Volume | 2.96M |
| Market Cap | 25.95M |
| PE | 2.46 |
| EPS | 1.51 |
| Moving Average 50 Days | 2.86 |
| Moving Average 200 Days | 2.07 |
| Change | 0.07 |
If you invested $1000 in Minerva Neurosciences, Inc. (NERV) 10 years ago, it would be worth $92.2 as of November 08, 2025 at a share price of $3.71. Whereas If you bought $1000 worth of Minerva Neurosciences, Inc. (NERV) shares 5 years ago, it would be worth $135.6 as of November 08, 2025 at a share price of $3.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
GlobeNewswire Inc.
Oct 21, 2025 12:00 PM GMT
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants.Minerva and the FDA have defined a path forward for roluperidone’s clinical development and NDA resubmission.Further $40 mil
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
GlobeNewswire Inc.
Nov 05, 2024 12:30 PM GMT
BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported busi